Review Article
Anti-EGFR Therapy: Mechanism and Advances in Clinical Efficacy in Breast Cancer
Table 2
Part A. Response to first-line
3-weekly Trastuzumab monotherapy from Baselga et al. [27]. CR: Complete response;
PR: Partial response; SD: Stable disease; CBR: Clinical benefit rate; PD: Progressive
disease; ORR: Overall response rate; ITT: Intent-to-treat population. Part B. Most
common treatment-related adverse events (n = 105), adapted from Baselga et al.
[27].
| (a) | ||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||
| *Data missing for 2 patients. †One patient with best response of SD in the main study period achieved CR in the 12-month follow-up period. Therefore, in the follow-up analysis, ORR was 20%. | ||||||||||||||||||||||||||||||||||||
| (b) | ||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||